{
    "organizations": [],
    "uuid": "b2f86f57b434c652243864ed9a658e0e259d5f5d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-medicinova-announces-phase-2b-tria/brief-medicinova-announces-phase-2b-trial-results-in-mn-166-idUSASB0C3PW",
    "ord_in_thread": 0,
    "title": "BRIEF-Medicinova Announces Phase 2B Trial results in MN-166 (Ibudilast)",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 1 (Reuters) - Medicinova Inc:\n* MEDICINOVA ANNOUNCES MN-166 (IBUDILAST) DEMONSTRATED A 26 PCT REDUCTION IN CONFIRMED DISABILITY PROGRESSION IN THE SPRINT-MS PHASE 2B TRIAL IN PROGRESSIVE MS: POTENTIAL BEST-IN-DISEASE DRUG Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-02T02:43:00.000+02:00",
    "crawled": "2018-02-02T03:01:06.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "medicinova",
        "inc",
        "medicinova",
        "announces",
        "ibudilast",
        "demonstrated",
        "pct",
        "reduction",
        "confirmed",
        "disability",
        "progression",
        "phase",
        "2b",
        "trial",
        "progressive",
        "m",
        "potential",
        "drug",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}